294 related articles for article (PubMed ID: 18322437)
1. Advances in the use of alemtuzumab in CLL.
Stilgenbauer S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
[No Abstract] [Full Text] [Related]
2. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
[TBL] [Abstract][Full Text] [Related]
3. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
4. Have we forgotten the purpose of phase III studies?
Flynn JM; Byrd JC
J Clin Oncol; 2007 Dec; 25(35):5553-5. PubMed ID: 17984184
[No Abstract] [Full Text] [Related]
5. The emerging role of alemtuzumab in chronic lymphocytic leukemia.
Nabhan C
Clin Lymphoma Myeloma; 2005 Sep; 6(2):115-21. PubMed ID: 16231849
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab in B-cell chronic lymphocytic leukemia.
Shapira I; Grossbard ML
Clin Lymphoma; 2004 Mar; 4(4):228-9. PubMed ID: 15072614
[No Abstract] [Full Text] [Related]
7. Alemtuzumab in chronic lymphocytic leukemia.
James DF; Kipps TJ
Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab in CLL and other lymphoid neoplasms.
Ravandi F; O'brien S
Cancer Invest; 2006 Nov; 24(7):718-25. PubMed ID: 17118783
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Thomas DA; Cortes J; Giles FJ; Wierda WG; Koller CA; Ferrajoli A; Browning M; Lerner S; Albitar M; Keating MJ
Cancer; 2003 Dec; 98(12):2657-63. PubMed ID: 14669286
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
[TBL] [Abstract][Full Text] [Related]
11. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
Montillo M; Schinkoethe T; Elter T
Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K; Dearden CE
Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
[TBL] [Abstract][Full Text] [Related]
13. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
Dumont FJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
[TBL] [Abstract][Full Text] [Related]
14. Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment.
Rai KR
Haematologica; 1999 Jun; 84 Suppl EHA-4():94-5. PubMed ID: 10907481
[No Abstract] [Full Text] [Related]
15. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
Laurenti L; Tarnani M; Innocenti I; Savino G; Battendieri R; Larocca LM; Chiusolo P; Sorà F; Sica S; Efremov D; Leone G
J Clin Oncol; 2008 Nov; 26(32):5299-301. PubMed ID: 18854557
[No Abstract] [Full Text] [Related]
17. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Robak T
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
Grey M
Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
[No Abstract] [Full Text] [Related]
19. Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia?
Oberoi SS; Abou Jawde RM
J Clin Oncol; 2008 Dec; 26(35):5827-8; author reply 5828-9. PubMed ID: 19001335
[No Abstract] [Full Text] [Related]
20. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.
Stilgenbauer S; Döhner H
N Engl J Med; 2002 Aug; 347(6):452-3. PubMed ID: 12167696
[No Abstract] [Full Text] [Related]
[Next] [New Search]